10 October 2024 Machine learning-enabled drug discovery and development company insitro has announced the execution of three strategic agreements with Eli Lilly.
Japanese biotech PeptiDream has entered into a license and collaboration agreement with US RNAi therapeutics company Alnylam Pharmaceuticals to discover and develop peptide-siRNA conjugates to create multiple opportunities to deliver RNAi therapeutics to tissues outside the liver. 31 July 2021
Danish allergy immunotherapy specialist ALK Abello has announced an exclusive licensing agreement with China Grand Pharmaceutical and Healthcare Holdings (Grandpharma), that will see ALK’s adrenaline auto-injector (AAI) Jext registered and launched in China, and will expand ALK's presence in the country. 31 July 2021
US drugmaker AbbVie announced financial results for the second quarter of 2021, showing that revenues were up 33.9% on a reported basis at $13.959 billion, beating the expectations of analysts polled by FactSet of $13.63 billion. 30 July 2021
US biopharma Vertex Pharmaceuticals has raised full-year 2021 guidance for product revenues from $7.2 billion to $7.4 billion upon presenting its second-quarter financial results. 30 July 2021
US pharma major Eli Lilly’s Loxo Oncology unit has signed a multi-year collaboration with San Diego-based Kumquat Biosciences on the discovery, development and commercialization of potential novel small molecule that stimulate tumor-specific immune responses. 30 July 2021
Japanese drugmaker Takeda closed 2% down after Tokyo’s trading day on Friday, having presented its financial results from the first quarter, under Japan’s April to March financial year. 30 July 2021
The UK genomics sector has released a report detailing the strength of research in this area, highlighting what it sees as a broad range of investment opportunities. 30 July 2021
The UK’s Competition and Markets Authority (CMA) has imposed over £100 million ($139 million) in fines after Advanz inflated the price of thyroid tablets, causing the National Health Service (NHS) and patients to lose out. 30 July 2021
Shares in Californian kidney specialist Ardelyx are up a quarter in pre-market trading, despite the firm receiving a Complete Response Letter (CRL) for its candidate tenapanor. 30 July 2021
The US Food and Drug Administration has approved Nucala (mepolizumab), a monoclonal antibody that targets interleukin-5 (IL-5), as a treatment for patients with chronic rhinosinusitis with nasal polyps (CRSwNP). 30 July 2021
Johnson & Johnson’s partner for manufacturing its coronavirus vaccine, Emergent BioSolutions, has announced it will be able to resume operations at its plant in Bayview, USA. 30 July 2021
US biotech major Gilead Sciences yesterday posting financials for second-quarter 2021, showing that revenues of $6.2 billion increased 21% compared to the same period in 2020. 30 July 2021
Japan’s Takeda Pharmaceutical and Frazier Healthcare Partners yesterday announced a collaboration to launch HilleVax, a biopharmaceutical company to develop and commercialize Takeda’s norovirus vaccine candidate. 30 July 2021
US biotech Arrowhead Pharmaceuticals today announced that it was granted Breakthrough Therapy designation (BTD) by the US Food and Drug Administration for ARO-AAT, also known as TAK-999, the company’s second-generation investigational RNA interference (RNAi) therapeutic. 29 July 2021
New data from a survey of patients prescribed medical cannabis to treat pain shows that 86% found it to be more effective than other medication that they had previously taken. 29 July 2021
Japan’s largest drugmaker Takeda Pharmaceutical says that the US Food and Drug Administration has granted Breakthrough Therapy designation (BTD) to TAK-994, its Phase II investiga00tional oral orexin agonist, which is designed to selectively target orexin 2 receptors. 29 July 2021
Belgian largest drugmaker UCB today reported financial results for the first half of 2021, which saw the firm’s shares gain 1.8% to 91.98 euros by late afternoon. 29 July 2021
British drugmaker AstraZeneca delivered strong revenue growth in the second quarter, taking in $8.2 billion, an increase of 31% from the same period last year. 29 July 2021
Danish dermatology specialist Leo Pharma has revealed plans to cut 200 jobs, marking the company’s fourth workforce reduction since 2022. 11 October 2024
Swiss generic and biosimilar medicines major Sandoz today announced that it has launched a generic paclitaxel formulation in the USA, the first generic to its reference medicine to be approved by the US Food and Drug Administration (FDA). 11 October 2024
California-based AI company Suki has raised $70 million in new funding to accelerate the growth of its AI-powered voice solutions in healthcare. 11 October 2024
Pfizer is to present initial findings from its CULTIVATE study of its sphingosine-1-phosphate (S1P) receptor modulator Velsipity (etrasimod) in Crohn’s disease (CD) at United European Gastroenterology Week 2024. 11 October 2024
Two US units of Israel’s Teva Pharmaceutical Industries have agreed to pay $450 million to resolve two matters that allege Teva violated the Anti-Kickback Statute (AKS) and the False Claims Act (FCA), the US Department of Justice (DoJ) announced yesterday. 11 October 2024
Switzerland-based KeyBioscience and US pharma major Eli Lilly have agreed to extend their collaboration on the development of dual amylin calcitonin receptor agonists (DACRA), a new class of potential treatments for obesity and related disorders. 11 October 2024
Booster Therapeutics, a biotechnology company pioneering a new class of proteasome activator medicines to treat neurodegenerative and other diseases, has launched with the support of a $15 million financing. 11 October 2024
South Korea’s Samsung Bioepis has released its Fourth Quarter 2024 Biosimilar Market Report, marking the seventh-edition of the Quarterly Biosimilar Market Report in the United States. 11 October 2024
German cancer specialist Immatics has announced the pricing of its $150 million public offering, with Jefferies, BofA Securities, and Leerink acting as joint book runners. 11 October 2024
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has approved Pfizer and BioNTech's latest COVID-19 vaccine, Comirnaty (KP.2). 11 October 2024
In what Astella Pharma calls “a landmark decision for advanced bladder cancer patients,” the Japanese drugmaker gained approval in the UK for its treatment regimen. 10 October 2024
Machine learning-enabled drug discovery and development company insitro has announced the execution of three strategic agreements with Eli Lilly. 10 October 2024
Pfizer released positive top line results from the final prespecified overall survival (OS) analysis of the TALAPRO-2 study of Talzenna (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with Xtandi (enzalutamide). 10 October 2024
Nanoscope Therapeutics says that, following a productive FDA meeting with the US Food and Drug Administration (FDA) for its clinical program evaluating MCO-010 for the treatment of retinitis pigmentosa (RP), the company will commence with submission of a Biologics License Application (BLA) in the first quarter of 2025. 10 October 2024
US healthcare giant Johnson & Johnson’s Tecvayli (teclistamab) has been recommended by the National Institute for Health and Care Excellence (NICE) as a first-line option to treat myeloma in England and Wales. 10 October 2024
Cancer start-up Black Diamond Therapeutics has announced a significant restructuring as part of its plan to focus resources on its lead drug, BDTX-1535. 10 October 2024